View Older Stories View More Recent Stories

May 29, 2020 08:01AM Regeneron (REGN) Announces Libtayo Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO
May 29, 2020 08:00AM Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
May 29, 2020 08:00AM Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
May 26, 2020 11:41AM Regeneron (REGN), Sanofi (SNY) Announce FDA Approves Dupixent as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
May 26, 2020 11:40AM Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
May 26, 2020 11:39AM FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
May 26, 2020 05:54AM Regeneron (REGN) Reports Dupixent (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
May 22, 2020 06:47PM Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
May 22, 2020 06:25PM Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
May 13, 2020 05:00PM Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
May 11, 2020 07:00AM Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
May 5, 2020 06:30AM Regeneron Reports First Quarter 2020 Financial and Operating Results
May 5, 2020 01:00AM Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
May 5, 2020 12:59AM Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Apr 29, 2020 07:00AM Regeneron Announces Upcoming Investor Conference Presentations
Apr 27, 2020 07:01AM Regeneron (REGN) Reports Ph.3 Trial of Libtayo (cemiplimab) as Monotherapy for First-Line Advanced NSCLC Stopped Early Due to Highly Significant Improvement in OS
Apr 27, 2020 07:00AM Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
Apr 27, 2020 06:59AM Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Apr 27, 2020 06:58AM Regeneron (REGN), Sanofi (SNY) U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara in Hospitalized COVID-19 Patients to Discontinue Lower-Dose, Continue Higher-Dose
Apr 27, 2020 06:58AM Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Apr 27, 2020 06:58AM Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Apr 16, 2020 07:01AM Regeneron (REGN) Announces FDA Accepts for Priority Review BLA for REGN-EB3 to Treat Ebola
Apr 16, 2020 07:00AM FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
Apr 8, 2020 06:04AM Regeneron (REGN), Zai Lab Report Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 6, 2020 05:00PM Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
Apr 3, 2020 06:00AM Sanofi (SNY) Reports Dupixent (dupilumab) Phase 3 Data Shows Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Apr 3, 2020 01:00AM Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
Apr 3, 2020 12:59AM Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Mar 30, 2020 11:47AM Regeneron (REGN) Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Mar 30, 2020 11:46AM Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Mar 30, 2020 09:55AM Regeneron (REGN) Gains After Treating First COVID-19 Patients Outside U.S. in Kevzara Trial
Mar 30, 2020 01:00AM Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 30, 2020 12:59AM First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 17, 2020 07:01AM Regeneron (REGN) Announces Important Advances in Novel COVID-19 Antibody Program, to Enter Human Clinical Studies by Early Summer
Mar 17, 2020 07:00AM Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
Mar 16, 2020 08:09AM Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19
Mar 16, 2020 08:02AM Sanofi (SNY), Regeneron (REGN) begin global Kevzara clinical trial program in patients with severe COVID-19
Mar 16, 2020 08:00AM Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19
Mar 3, 2020 04:05PM Regeneron Announces Upcoming Investor Conference Presentations
Feb 12, 2020 04:01PM Regeneron Announces Upcoming Investor Conference Presentations
Feb 10, 2020 06:15AM Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg
Feb 8, 2020 05:00PM EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
Feb 6, 2020 06:30AM Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
Feb 4, 2020 09:04AM Regeneron (REGN) Confirms Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Feb 4, 2020 09:00AM Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Jan 28, 2020 06:14AM Regeneron (REGN), Sanofi (SNY) Report FDA Accepts Priority Review Dupixent (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Jan 28, 2020 01:00AM Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
View More Recent Stories View Older Stories